We are setting out to Beat AML.


WHY?

Despite advances in treating other blood cancers, the standard of care for AML patients has not changed in 40 years.

It’s not for lack of effort. LLS has been on the forefront of the battle against AML for decades. But, AML is a complex grouping of more than 10 different prominent subtypes of blood cancer, and many other more rare ones, which causes more than 10,000 deaths in the U.S. annually. The survival prognosis is very poor.


HOW?

Only LLS has the leadership and experience to convene an unprecedented collaboration of renowned academic researchers, pharmaceutical companies, genomics experts and government, to bring to bear all of our combined resources to develop more effective, precisely targeted treatments for patients diagnosed with AML.

LLS’s Beat AML initiative employs advanced genomic technology to understand the genetic mutations in AML and identify targeted therapies to inhibit these mutations and more effectively treat the cancer. The collaboration continues to expand to include multiple academic institutions and pharmaceutical companies.


WHY LLS?

LLS began funding AML research at our inception more than 66 years ago, and about 26 percent of our annual research budget goes to AML research. In the past five years alone we have invested nearly $100 million in AML research, with a focus on understanding the underlying causes of the disease to develop better therapies and save more lives.

LLS had the vision to make a “down payment” for patients with AML in 2009 by partnering with Celator Pharmaceuticals to advance CPX-351, an innovative formulation of two existing therapies, which recently outperformed standard therapy in a Phase 3 clinical trial for patients with secondary AML, a high-risk subtype of the disease. This investment has the potential to pay off significantly as the first new treatment in 40 years for patients diagnosed with AML.

Milestones in AML Treatments

timeline

Cytarabine/Daunorubicin: Development of 7+3 protocol for AML — 40 years later for this chemotherapy combination still remains the standard of care for AML patients.

Bone Marrow Transplant: FDA approval of Mylotarg (gentuzumub) – is a drug-linked monoclonal antibody (an antibody-drug conjugate) that was used to treat AML patients from 2000 to 2010. It was withdrawn from market in June 2010 when a clinical trial showed the drug increased patient death and added no benefit over conventional cancer therapies.

Mylotarg: Helps the immune system find the cancer cells

Celator: LLS enters partnership with Celator Pharmaceuticals in 2009 to fund a Phase 2 clinical trial for CPX-351, an innovative reformulation of the chemotherapy drugs cytarabine and daunorubicin.

Celator: LLS enters second agreement with Celator in 2012 to fund a Phase 3 trial of CPX-351 for a high-risk subset of AML patients.

Beat AML 2013: LLS launches unprecedented attack on AML and engages Brian Druker, M.D., OHSU Knight Cancer Institute in Oregon, in a major novel collaboration – Beat AML – to use advanced genomic analysis to identify genetic mutations of AML and test different drugs to develop precision medicine approach to treat AML patients.

T-cell Immunotherapy: Stephen Gottschalk, MD., Baylor College of Medicine, awarded Translations Research Grant to study adoptive T-cell based immunotherapies in AML.

Celator: Positive Phase III results from CPX-351 clinical trial announced March 2016.

Beat AML 2016: Led by LLS, Beat AML collaboration expands to include multiple institutions, drug companies, a company to provide genetic analysis, the FDA, and a clinical research organization, and launches a groundbreaking Master Trial to test a number of investigational targeted drugs to treat patients with AML.